Storia in 3 fonti

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion | Fortune

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.

Raccontata da

morningstar.com

fortune.com

koreaherald.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

fortune.comStai leggendo1 mese fa

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion |…

Insilico signs $2.5B deal with Korea's SK Biopharmaceuticals for AI neuroimmune drug discovery (second mega pharma partnership). For tech leaders: AI cuts pre-clinical R&D by years; Korean biotech capital surge reshapes competitive landscape toward Asia.

originale

morningstar.com1 mese fa

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5…

Insilico and SK Biopharmaceuticals announce $2.5B partnership for AI-powered CNS neuroimmune drug discovery using Pharma.AI. The 12-18 month preclinical candidate timeline versus 2.5-4 years traditional signals pharma AI advancing to commercial-scale viability.

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion | Fortune

Confronto fonti

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion |…

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5…

Timeline cronologica

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune…

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion | Fortune

[Bio USA] SK Biopharmaceuticals doubles down on AI, open innovation

[Bio USA] SK Biopharmaceuticals doubles down on AI, open innovation